News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
599,020 Results
Type
Article (43077)
Company Profile (316)
Press Release (555627)
Multimedia
Podcasts (70)
Webinars (11)
Section
Business (167722)
Career Advice (2465)
Deals (30338)
Drug Delivery (109)
Drug Development (78800)
Employer Resources (148)
FDA (14439)
Job Trends (12991)
News (296297)
Policy (28654)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (5)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (13)
2024 Biotech Beach Digital (6)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (5)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2685)
Academic (1)
Accelerated approval (6)
Adcomms (26)
Allergies (84)
Alliances (43016)
ALS (96)
Alzheimer's disease (1446)
Antibody-drug conjugate (ADC) (143)
Approvals (14427)
Artificial intelligence (256)
Autoimmune disease (26)
Automation (16)
Bankruptcy (326)
Best Places to Work (10675)
BIOSECURE Act (16)
Biosimilars (96)
Biotechnology (257)
Bladder cancer (84)
Brain cancer (29)
Breast cancer (283)
Cancer (2284)
Cardiovascular disease (192)
Career advice (2072)
Career pathing (32)
CAR-T (159)
Cell therapy (440)
Cervical cancer (18)
Clinical research (63890)
Collaboration (829)
Compensation (382)
Complete response letters (25)
COVID-19 (2571)
CRISPR (46)
C-suite (257)
Cystic fibrosis (102)
Data (2196)
Decentralized trials (2)
Denatured (15)
Depression (52)
Diabetes (265)
Diagnostics (5833)
Digital health (15)
Diversity (4)
Diversity, equity & inclusion (40)
Drug discovery (123)
Drug pricing (104)
Drug shortages (24)
Duchenne muscular dystrophy (99)
Earnings (61737)
Editorial (40)
Employer branding (20)
Employer resources (135)
Events (90142)
Executive appointments (738)
FDA (15634)
Featured Employer (42)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (735)
Gene editing (112)
Generative AI (21)
Gene therapy (330)
GLP-1 (745)
Government (4267)
Grass and pollen (5)
Guidances (52)
Healthcare (17255)
Huntington's disease (25)
IgA nephropathy (31)
Immunology and inflammation (136)
Indications (30)
Infectious disease (2718)
Inflammatory bowel disease (147)
Inflation Reduction Act (11)
Influenza (52)
Intellectual property (98)
Interviews (528)
IPO (14252)
IRA (46)
Job creations (2747)
Job search strategy (1696)
Kidney cancer (11)
Labor market (21)
Layoffs (456)
Leadership (22)
Legal (6085)
Liver cancer (76)
Lung cancer (332)
Lymphoma (147)
Machine learning (7)
Management (52)
Manufacturing (285)
MASH (73)
Medical device (11146)
Medtech (11150)
Mergers & acquisitions (16601)
Metabolic disorders (705)
Multiple sclerosis (79)
NASH (23)
Neurodegenerative disease (105)
Neuropsychiatric disorders (34)
Neuroscience (2017)
NextGen: Class of 2025 (5954)
Non-profit (4133)
Northern California (2436)
Now hiring (36)
Obesity (374)
Opinion (238)
Ovarian cancer (76)
Pain (88)
Pancreatic cancer (83)
Parkinson's disease (157)
Partnered (20)
Patents (229)
Patient recruitment (107)
Peanut (47)
People (54079)
Pharmaceutical (55)
Pharmacy benefit managers (13)
Phase I (20058)
Phase II (28212)
Phase III (21029)
Pipeline (1180)
Policy (141)
Postmarket research (2395)
Preclinical (8501)
Press Release (60)
Prostate cancer (108)
Psychedelics (37)
Radiopharmaceuticals (257)
Rare diseases (408)
Real estate (4503)
Recruiting (60)
Regulatory (20402)
Reports (25)
Research institute (2278)
Resumes & cover letters (361)
Rett syndrome (5)
RNA editing (5)
RSV (40)
Schizophrenia (76)
Series A (128)
Series B (85)
Service/supplier (3)
Sickle cell disease (55)
Southern California (2186)
Special edition (13)
Spinal muscular atrophy (153)
Sponsored (28)
Startups (3179)
State (2)
Stomach cancer (14)
Supply chain (61)
Tariffs (33)
The Weekly (54)
United States (21215)
Vaccines (665)
Venture capitalists (41)
Weight loss (255)
Women's health (26)
Worklife (16)
Date
Today (185)
Last 7 days (824)
Last 30 days (2571)
Last 365 days (31448)
2025 (10001)
2024 (33554)
2023 (37504)
2022 (48407)
2021 (52035)
2020 (50006)
2019 (42511)
2018 (32046)
2017 (29623)
2016 (28219)
2015 (32950)
2014 (25391)
2013 (20578)
2012 (21802)
2011 (22728)
2010 (20440)
Location
Africa (748)
Alabama (54)
Alaska (4)
Arizona (169)
Arkansas (12)
Asia (36455)
Australia (7243)
California (5660)
Canada (1919)
China (505)
Colorado (249)
Connecticut (239)
Delaware (145)
Europe (81758)
Florida (840)
Georgia (182)
Idaho (55)
Illinois (483)
India (24)
Indiana (270)
Iowa (8)
Japan (157)
Kansas (94)
Kentucky (21)
Louisiana (10)
Maine (53)
Maryland (842)
Massachusetts (4200)
Michigan (199)
Minnesota (342)
Mississippi (2)
Missouri (79)
Montana (24)
Nebraska (22)
Nevada (56)
New Hampshire (66)
New Jersey (1622)
New Mexico (25)
New York (1614)
North Carolina (921)
North Dakota (6)
Northern California (2436)
Ohio (176)
Oklahoma (10)
Oregon (33)
Pennsylvania (1223)
Puerto Rico (12)
Rhode Island (30)
South America (1022)
South Carolina (19)
South Dakota (1)
Southern California (2186)
Tennessee (90)
Texas (823)
Utah (170)
Virginia (133)
Washington D.C. (55)
Washington State (518)
West Virginia (3)
Wisconsin (47)
599,020 Results for "cascadian therapeutics formally known as oncothyreon".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
May 1, 2025
·
6 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025
March 27, 2025
·
3 min read
Press Releases
Know Labs Technology Licensing (KTL) Announces Formalized Client Engagement
February 6, 2025
·
7 min read
Press Releases
CB Scientific Inc. (CBSC) Formally Launches Next Generation MyCardia AT Cardiac Monitor
February 25, 2025
·
4 min read
Business
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
Chromocell Therapeutics Corp. today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.
March 21, 2024
·
5 min read
Press Releases
BioRay’s ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
February 10, 2025
·
2 min read
BioMidwest
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.
May 29, 2024
·
5 min read
Immunology and inflammation
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO
Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 and IL-13 signaling, which in turn are known inflammatory targets.
January 13, 2025
·
2 min read
·
Tristan Manalac
Drug shortages
Compounders Sue FDA for Declaring Ozempic, Wegovy Shortage Over
The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year after the FDA formally ended the tirzepaptide shortage.
February 25, 2025
·
2 min read
·
Tristan Manalac
1 of 59,902
Next
